Dimethylformamide → HCID 54525087, compound
Reaction equation
[CH2:1]([NH2:4])[CH2:2][CH3:3].Cl[CH2:6][C:7]1[O:11][N:10]=[C:9]([C:12]2[N:13]=[CH:14][N:15]3[C:21]4[CH:22]=[CH:23][S:24][C:20]=4[C:19](=[O:25])[N:18]([CH3:26])[CH2:17][C:16]=23)[N:8]=1.[CH3:27]N(C)C=O>>[CH2:1]([NH:4][CH2:6][C:7]1[O:11][N:10]=[C:9]([C:12]2[N:13]=[CH:14][N:15]3[C:21]4[CH:22]=[CH:23][S:24][C:20]=4[C:19](=[O:25])[N:18]4[CH2:26][CH2:27][C@H:17]4[C:16]=23)[N:8]=1)[CH2:2][CH3:3]Participants
Procedure
0.73 ml (9 mmol) of propylamine was added to a suspension of 1 g (3 mmol) of 3-(5-chloromethyl-1,2,4-oxadiazol-3-yl)-5-methyl-5,6-dihydro-4H-imidazo[1,5-a]thieno[2,3-f][1,4]diazepin-6-one in 30 ml of N,N-dimethylformamide and the mixture was stirred at room temperature for 12 hours. The solution was evaporated and the residue was partitioned between methylene chloride and 2N sodium carbonate solution. The aqueous solution was extracted with methylene chloride and the organic phases were dried, filtered and evaporated. The residue was chromatographed (silica gel, methylene chloride/methanol/aqueous ammonia 140:10:1). There was obtained 0.86 g (80%) of (S)-1-(5-propylaminomethyl-1,2,4-oxadiazol-3-yl)-11,11a-dihydro-8H, 10H-azeto[1,2-a]imidazo[5,1-c]thieno[3,2-e][1,4]diazepin-8-one as a colourless foam, Rf=0.38 (silica gel, methylene chloride/methanol/aqueous ammonia 140:10:1).
Workup
- customThe solution was evaporated
- customthe residue was partitioned between methylene chloride and 2N sodium carbonate solution
- extractionThe aqueous solution was extracted with methylene chloride
- customthe organic phases were dried
- filtrationfiltered
- customevaporated
- customThe residue was chromatographed (silica gel, methylene chloride/methanol/aqueous ammonia 140:10:1)
Sources & evidence
- ORD record
- ord-2a22639db4d64d6b97729f22928e3fed
- Source dataset
- uspto-grants-1997_09
- Patent number
- US05665718
Reaction notes
Loading…